These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

395 related articles for article (PubMed ID: 24854434)

  • 41. Cannabidiol Treatment for Refractory Seizures in Sturge-Weber Syndrome.
    Kaplan EH; Offermann EA; Sievers JW; Comi AM
    Pediatr Neurol; 2017 Jun; 71():18-23.e2. PubMed ID: 28454984
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Adjunctive Cannabidiol in Patients with Dravet Syndrome: A Systematic Review and Meta-Analysis of Efficacy and Safety.
    Lattanzi S; Brigo F; Trinka E; Zaccara G; Striano P; Del Giovane C; Silvestrini M
    CNS Drugs; 2020 Mar; 34(3):229-241. PubMed ID: 32040850
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome.
    Devinsky O; Patel AD; Thiele EA; Wong MH; Appleton R; Harden CL; Greenwood S; Morrison G; Sommerville K;
    Neurology; 2018 Apr; 90(14):e1204-e1211. PubMed ID: 29540584
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cannabidiol--antiepileptic drug comparisons and interactions in experimentally induced seizures in rats.
    Consroe P; Wolkin A
    J Pharmacol Exp Ther; 1977 Apr; 201(1):26-32. PubMed ID: 850145
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cannabidiol Treatment for Refractory Epilepsies in Pediatrics.
    Raucci U; Pietrafusa N; Paolino MC; Di Nardo G; Villa MP; Pavone P; Terrin G; Specchio N; Striano P; Parisi P
    Front Pharmacol; 2020; 11():586110. PubMed ID: 33117180
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Efficacy of Phytocannabinoids in Epilepsy Treatment: Novel Approaches and Recent Advances.
    Farrelly AM; Vlachou S; Grintzalis K
    Int J Environ Res Public Health; 2021 Apr; 18(8):. PubMed ID: 33920188
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cognitive and behavioral effects of cannabidiol in patients with treatment-resistant epilepsy.
    Metternich B; Wagner K; Geiger MJ; Hirsch M; Schulze-Bonhage A; Klotz KA
    Epilepsy Behav; 2021 Jan; 114(Pt A):107558. PubMed ID: 33246899
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Drug-drug interaction between clobazam and cannabidiol in children with refractory epilepsy.
    Geffrey AL; Pollack SF; Bruno PL; Thiele EA
    Epilepsia; 2015 Aug; 56(8):1246-51. PubMed ID: 26114620
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Lamotrigine adjunctive therapy among children and adolescents with primary generalized tonic-clonic seizures.
    Trevathan E; Kerls SP; Hammer AE; Vuong A; Messenheimer JA
    Pediatrics; 2006 Aug; 118(2):e371-8. PubMed ID: 16847080
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Advances and Challenges of Cannabidiol as an Anti-Seizure Strategy: Preclinical Evidence.
    Zavala-Tecuapetla C; Luna-Munguia H; López-Meraz ML; Cuellar-Herrera M
    Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555823
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cannabis and epilepsy.
    Thomas RH; Cunningham MO
    Pract Neurol; 2018 Dec; 18(6):465-471. PubMed ID: 30337476
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Marijuana Use in Epilepsy: The Myth and the Reality.
    Detyniecki K; Hirsch L
    Curr Neurol Neurosci Rep; 2015 Oct; 15(10):65. PubMed ID: 26299273
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Expectations and knowledge of cannabidiol therapy for childhood epilepsy - A German caregiver survey.
    Klotz KA; Schönberger J; Nakamura L; San Antonio-Arce V; Bast T; Wiemer-Kruel A; Schubert-Bast S; Borggraefe I; Syrbe S; Jacobs J
    Epilepsy Behav; 2020 Oct; 111():107268. PubMed ID: 32645621
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A Phase 2, Double-Blind, Placebo-Controlled Trial to Investigate Potential Drug-Drug Interactions Between Cannabidiol and Clobazam.
    VanLandingham KE; Crockett J; Taylor L; Morrison G
    J Clin Pharmacol; 2020 Oct; 60(10):1304-1313. PubMed ID: 32652616
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial.
    Rog DJ; Nurmikko TJ; Young CA
    Clin Ther; 2007 Sep; 29(9):2068-79. PubMed ID: 18035205
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Efficacy of CBD-enriched medical cannabis for treatment of refractory epilepsy in children and adolescents - An observational, longitudinal study.
    Hausman-Kedem M; Menascu S; Kramer U
    Brain Dev; 2018 Aug; 40(7):544-551. PubMed ID: 29674131
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Rufinamide: a new antiepileptic medication for the treatment of seizures associated with lennox-gastaut syndrome.
    Wisniewski CS
    Ann Pharmacother; 2010 Apr; 44(4):658-67. PubMed ID: 20233912
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cannabidiol: metabolism and clinical efficacy in epileptic patients.
    Dell'Isola GB; Verrotti A; Sciaccaluga M; Dini G; Ferrara P; Parnetti L; Costa C
    Expert Opin Drug Metab Toxicol; 2024 Mar; 20(3):119-131. PubMed ID: 38465404
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Does the addition of cannabidiol to conventional antiepileptic drug treatment reduce seizure frequency in dogs with epilepsy?
    Morrow L; Belshaw Z
    Vet Rec; 2020 May; 186(15):492-493. PubMed ID: 32358117
    [No Abstract]   [Full Text] [Related]  

  • 60. Cannabidiol in inflammatory bowel diseases: a brief overview.
    Esposito G; Filippis DD; Cirillo C; Iuvone T; Capoccia E; Scuderi C; Steardo A; Cuomo R; Steardo L
    Phytother Res; 2013 May; 27(5):633-6. PubMed ID: 22815234
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.